论文部分内容阅读
目的:比较重组人干扰素-α2b凝胶和壳聚糖凝胶对宫颈柱状上皮异位患者伴宫颈炎的临床疗效。方法:选取2016年2月—10月期间诊治的宫颈柱状上皮异位伴宫颈炎患者180例临床资料,将其随机分为观察组和对照组(每组90例);观察组患者给予重组人干扰素-α2b凝胶治疗,对照组患者给予壳聚糖凝胶治疗,治疗4月时来医院门诊复查,比较两组患者治疗后的总有效率、显效率、临床症状体征缓解率、药物不良反应发生率,以及治疗前后宫颈病灶面积的平均变化率。结果:观察组患者治疗后的总有效率、显效率和临床症状体征缓解率均明显高于对照组(P<0.05),宫颈病灶面积的平均缩小率明显高于对照组(P<0.05),不良反应的发生率明显低于对照组(P<0.05)。结论:重组人干扰素-α2b凝胶用于宫颈柱状上皮异位伴宫颈炎患者的临床疗效优于和壳聚糖凝胶,临床症状体征与宫颈病灶明显缓解,用药期间不良反应的发生率较低。
Objective: To compare the clinical efficacy of recombinant human interferon-α2b gel and chitosan gel in patients with cervical columnar epithelial ectopic patients with cervicitis. Methods: The clinical data of 180 patients with cervical columnar epithelial ectopic and cervicitis diagnosed and treated between February and October 2016 were selected and randomly divided into observation group and control group (90 cases in each group). Patients in observation group were given recombinant human Interferon-α2b gel treatment, the control group of patients given chitosan gel therapy, treatment of 4 months to the hospital for review, compared two groups of patients after treatment, the total effective rate, markedly effective, clinical symptoms and signs of remission, drug dysfunction Reaction rate, and the average change rate of cervical lesion area before and after treatment. Results: The total effective rate, markedly effective rate and symptom relief rate of clinical symptoms in observation group were significantly higher than those in control group (P <0.05). The average reduction rate of cervical lesion area was significantly higher than that in control group (P <0.05) The incidence of adverse reactions was significantly lower than that of the control group (P <0.05). Conclusion: The clinical efficacy of recombinant human interferon-α2b gel in patients with cervical columnar epithelial ectopic and cervicitis is better than that of chitosan gel, clinical symptoms and signs of cervical lesions were significantly relieved, the incidence of adverse reactions during the treatment low.